[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@NattaCop](/creator/twitter/NattaCop) "$ocgn many are confused saying didnt we go XX consecutive days above $X. Youre not crazy we did stay above $X for what usually is required by NASDAQ. This is not a SEC rule though its not black and white like that. NASDAQs exchange their rules and their discretion. Ive seen NASDAQ grant us compliance with far less bullish news and closer to $X closing days. This time was they wanted a little more for whatever reason. Important thing is we were granted the XXX day extension and have a mountain of good news on the way. This is not a problem for us we will be just fine. 💯 🍻"  [@NattaCop](/creator/x/NattaCop) on [X](/post/tweet/1940164500554228056) 2025-07-01 21:43:58 UTC 1130 followers, 1663 engagements "$ocgn X BLAs each year for the next X years. Buy now or chase later. Also 🔥 post Ocugen 👏"  [@NattaCop](/creator/x/NattaCop) on [X](/post/tweet/1943379557576569193) 2025-07-10 18:39:27 UTC 1131 followers, 2204 engagements "$ocgn The commercialization phase has begun. New VP Abhi Gupta helped build Pfizers $5.5B gene therapy portfolio led a 200+ global team at Syneos and held leadership roles at J&J and Regeneron. You dont bring in someone like that unless youre gearing up to go worldwide. 🍻"  [@NattaCop](/creator/x/NattaCop) on [X](/post/tweet/1945120886425837969) 2025-07-15 13:58:52 UTC 1132 followers, 2785 engagements "$ocgn Spend billions now to save hundreds of billions from being burnt yearly later. 🍻"  [@NattaCop](/creator/x/NattaCop) on [X](/post/tweet/1940410145294700815) 2025-07-02 14:00:04 UTC 1131 followers, 2478 engagements "$ocgn Some call the latest news fluff tossing wild takes like not relevant. They post nonstop about this stock but couldnt tell you what words like pivotal/Orphan/RMAT/or FDA reforms even mean. Most stare at charts all day role playing as biotech experts while billion dollar catalysts stare right at them. OCU410ST dosed its first patient in their pivotal Phase 2/3 trial. Pivotal = BLA can be filed right after if successful. Endpoints are XX months only XX patients and dosing has started. No approved treatment exists for Stargardt a disease blinding children. With orphan pricing ($1.25M$1.5M)"  [@NattaCop](/creator/x/NattaCop) on [X](/post/tweet/1947140315938537739) 2025-07-21 03:43:22 UTC 1131 followers, 2627 engagements "$ocgn Luxturna treated XXX% of the RP market thats a global population of under 10K patients. They still did $120M in year one got acquired for $1.4B then later bought by Roche for $4.8B for a one mutation product Now compare that to Ocu400/410/410ST which are gene agnostic and target broad IRD populations in RP GA and Stargardt. Just Ocu410ST alone is going after a market 30x50x the size Luxturna targeted Factor in FDA reforms cutting BLA reviews to X months orphan pricing now securing prices at $1.25M+ no matter how many diseases a drug treats and rewards like priority review vouchers that"  [@NattaCop](/creator/x/NattaCop) on [X](/post/tweet/1947390858262942006) 2025-07-21 20:18:56 UTC 1132 followers, 1148 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@NattaCop
"$ocgn many are confused saying didnt we go XX consecutive days above $X. Youre not crazy we did stay above $X for what usually is required by NASDAQ. This is not a SEC rule though its not black and white like that. NASDAQs exchange their rules and their discretion. Ive seen NASDAQ grant us compliance with far less bullish news and closer to $X closing days. This time was they wanted a little more for whatever reason. Important thing is we were granted the XXX day extension and have a mountain of good news on the way. This is not a problem for us we will be just fine. 💯 🍻"
@NattaCop on X 2025-07-01 21:43:58 UTC 1130 followers, 1663 engagements
"$ocgn X BLAs each year for the next X years. Buy now or chase later. Also 🔥 post Ocugen 👏" @NattaCop on X 2025-07-10 18:39:27 UTC 1131 followers, 2204 engagements
"$ocgn The commercialization phase has begun. New VP Abhi Gupta helped build Pfizers $5.5B gene therapy portfolio led a 200+ global team at Syneos and held leadership roles at J&J and Regeneron. You dont bring in someone like that unless youre gearing up to go worldwide. 🍻" @NattaCop on X 2025-07-15 13:58:52 UTC 1132 followers, 2785 engagements
"$ocgn Spend billions now to save hundreds of billions from being burnt yearly later. 🍻" @NattaCop on X 2025-07-02 14:00:04 UTC 1131 followers, 2478 engagements
"$ocgn Some call the latest news fluff tossing wild takes like not relevant. They post nonstop about this stock but couldnt tell you what words like pivotal/Orphan/RMAT/or FDA reforms even mean. Most stare at charts all day role playing as biotech experts while billion dollar catalysts stare right at them. OCU410ST dosed its first patient in their pivotal Phase 2/3 trial. Pivotal = BLA can be filed right after if successful. Endpoints are XX months only XX patients and dosing has started. No approved treatment exists for Stargardt a disease blinding children. With orphan pricing ($1.25M$1.5M)" @NattaCop on X 2025-07-21 03:43:22 UTC 1131 followers, 2627 engagements
"$ocgn Luxturna treated XXX% of the RP market thats a global population of under 10K patients. They still did $120M in year one got acquired for $1.4B then later bought by Roche for $4.8B for a one mutation product Now compare that to Ocu400/410/410ST which are gene agnostic and target broad IRD populations in RP GA and Stargardt. Just Ocu410ST alone is going after a market 30x50x the size Luxturna targeted Factor in FDA reforms cutting BLA reviews to X months orphan pricing now securing prices at $1.25M+ no matter how many diseases a drug treats and rewards like priority review vouchers that" @NattaCop on X 2025-07-21 20:18:56 UTC 1132 followers, 1148 engagements